FEED ENvue Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · OTC · SEC CIK 1326706 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-17.7%
TTM net income YoY-154.6%
TTM EPS YoY72.9%
Revenue 3-yr CAGR44.2%
Net income 3-yr CAGR—
Margins
Gross margin-26.1%
Operating margin-1,362.7%
Net margin-1,093.6%
FCF margin-609.8%
EBITDA margin-1,313.3%
Returns
ROE-59.1%
ROA-46.9%
ROIC (approx.)-62.7%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets19.9%
Debt / equity0.00x
Current ratio0.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.55x
Accruals ratio-20.9%
Payout ratio—
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $239,000 | $653,000 | $312,000 | $722,000 | $494,000 | $1.02M | $444,000 | $376,000 |
| Cost of revenue | $505,000 | $708,000 | $682,000 | $533,000 | $529,000 | $656,000 | $161,000 | $243,000 |
| Gross profit | -$266,000 | -$55,000 | -$370,000 | $189,000 | -$35,000 | $369,000 | $283,000 | $133,000 |
| R&D expense | $510,000 | $468,000 | $39,000 | $221,000 | $1.02M | $530,000 | $352,000 | $249,000 |
| SG&A expense | $3.50M | $2.42M | $2.64M | $1.40M | $2.25M | $1.34M | $1.13M | $673,000 |
| Operating income | -$5.47M | -$3.71M | -$14.81M | -$2.25M | -$3.98M | -$1.85M | -$1.37M | -$970,000 |
| Interest expense | $30,000 | $36,000 | — | $53,000 | $144,000 | $53,000 | $34,000 | $33,000 |
| Pretax income | -$4.90M | -$3.79M | -$13.27M | $545,000 | -$3.91M | -$1.86M | -$1.43M | -$995,000 |
| Income tax | -$2,000 | $33,000 | -$419,000 | $35,000 | $62,000 | $15,000 | $5,000 | $3,000 |
| Net income | -$4.90M | -$3.82M | -$12.85M | $510,000 | -$3.97M | -$1.87M | -$1.43M | -$998,000 |
| EBITDA | -$5.25M | -$3.49M | -$14.56M | -$1.99M | -$3.61M | -$1.83M | -$1.37M | -$970,000 |
| EPS (basic) | -1.98 | -6.88 | — | -0.91 | -1.03 | -29.90 | — | -3.56 |
| EPS (diluted) | -1.98 | -6.88 | — | -0.91 | -1.03 | -29.90 | — | -3.56 |
| Weighted avg. shares (diluted) | 6.16M | 3.29M | — | 858,434 | 484,566 | 62,615 | — | 280,318 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.08M | $2.23M | $4.22M | $6.95M | $4.03M | $571,000 | $752,000 | $1.30M |
| Receivables | $205,000 | $332,000 | $289,000 | $252,000 | $115,000 | $358,000 | $98,000 | $580,000 |
| Inventory | $2.58M | $2.27M | $2.34M | $2.24M | $2.21M | $2.02M | $2.19M | $2.25M |
| Current assets | $4.82M | $6.20M | $7.27M | $10.02M | $6.89M | $3.86M | $3.33M | $4.38M |
| PP&E, net | $145,000 | $127,000 | $119,000 | $124,000 | $112,000 | $125,000 | $9,000 | $9,000 |
| Goodwill | $29.08M | $29.08M | $29.08M | $38.63M | $38.63M | $33.91M | — | — |
| Intangibles | $3.96M | $4.17M | $4.38M | $5.28M | $5.52M | $5.88M | — | — |
| Total assets | $38.41M | $39.87M | $41.12M | $54.38M | $51.48M | $44.10M | $3.63M | $4.68M |
| Current liabilities | $7.30M | $6.87M | $6.66M | $11.64M | $6.54M | $8.20M | $2.72M | $2.52M |
| Long-term debt | — | — | — | — | — | $1.25M | — | — |
| Total debt | — | — | — | — | — | $1.25M | — | — |
| Total liabilities | $7.65M | $7.86M | $7.63M | $11.92M | $11.01M | $8.43M | $3.00M | $2.81M |
| Shareholders' equity | $30.76M | $32.02M | $33.50M | $42.46M | $40.48M | $35.67M | $627,000 | $1.87M |
| Net debt | — | — | — | — | — | $683,863 | — | — |
| Shares outstanding | 8.19M | 3.70M | 1.10M | 1.01M | 787,359 | 734,025 | 37,894 | 2.78M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.69M | -$4.31M | -$2.68M | -$1.97M | -$3.38M | -$1.34M | -$548,000 | -$836,000 |
| Capital expenditure | $27,000 | $17,000 | $23,000 | $28,000 | $4,000 | $5,000 | $0 | $0 |
| Free cash flow | -$2.72M | -$4.33M | -$2.70M | -$2.00M | -$3.39M | -$1.35M | -$548,000 | -$836,000 |
| Investing cash flow | -$27,000 | -$17,000 | -$23,000 | -$28,000 | -$4,000 | $143,000 | $0 | $0 |
| Financing cash flow | $1.59M | $2.34M | -$34,000 | $4.92M | $6.85M | $1.05M | $0 | -$27,000 |
| Depreciation & amortization | $219,000 | $217,000 | $258,000 | $257,000 | $364,000 | $18,000 | $0 | $0 |
| Stock-based compensation | — | — | — | — | — | — | $191,000 | $58,000 |
Free plan shows the latest 8 periods; Pro shows all 50 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.